Investors Inquire about Jinjia's Plan for Domestic E-cigarette Sales

Business by 2FIRSTS.ai
May.15.2024
Investors Inquire about Jinjia's Plan for Domestic E-cigarette Sales
Investors inquire about Jinjia (002191) applying to sell its own e-cigarette brand domestically this year, company plans overseas sales.

Recently, investors inquired on the investor interaction platform about whether Jinjia Group (002191) has plans to reapply for domestic sales of its own e-cigarette brand this year.

Investors Inquire about Jinjia's Plan for Domestic E-cigarette Sales
Question and Answer | Image source: Interactive Easy

 

In response, Jingjia Corporation stated that, based on the relevant e-cigarette regulations in China and considering market conditions, the company's own brand of e-cigarette products are not sold domestically and are primarily marketed towards overseas regions.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

UK Experts Raise Concerns Over High-Dose Nicotine Pouches Amid Rising Sales
UK Experts Raise Concerns Over High-Dose Nicotine Pouches Amid Rising Sales
According to The Guardian, health experts in the UK are warning about the potential health effects of high-dose nicotine pouches as their sales continue to rise. Recent studies show teenagers reporting nicotine rushes, sickness and fainting, while researchers say packaging and marketing increasingly appeal to younger age groups. Although viewed as less harmful than cigarettes, experts remain concerned about their use among non-smokers, especially adolescents.
Nov.13 by 2FIRSTS.ai
Maldives Implements World's First Generational Prohibition on Tobacco, Banning Sales and Smoking for Those Born After 2007
Maldives Implements World's First Generational Prohibition on Tobacco, Banning Sales and Smoking for Those Born After 2007
The Maldives has implemented a generational tobacco ban, effective November 1, 2025, making it the only country to permanently prohibit anyone born on or after January 1, 2007 from buying or using tobacco. Initiated by President Mohamed Muizzu, the policy aims to create a tobacco-free generation and includes a nationwide ban on e-cigarettes, with fines up to 50,000 rufiyaa (US$3,200) for violations.
Nov.03 by 2FIRSTS.ai
CSUR, the Research Institute Supporting Juul’s PMTA Research, Outlines a New Pathway for Nicotine Pouches
CSUR, the Research Institute Supporting Juul’s PMTA Research, Outlines a New Pathway for Nicotine Pouches
CSUR—the Research Institute Supporting Juul and NJOY’s successful PMTAs—assessed FDA’s pilot for nicotine pouches. The program expedites premarket review by deferring behavioral data to post-market reporting. CSUR says this could speed authorizations, but manufacturers must still produce behavioral and real-world evidence after a Marketing Granted Order to maintain compliance with public-health standards.
Nov.04
Juul, NJOY and Altria Clash Over Use of UCSF Public Documents in U.S. Patent Litigation
Juul, NJOY and Altria Clash Over Use of UCSF Public Documents in U.S. Patent Litigation
Juul Labs has asked a U.S. federal court to prevent NJOY and Altria from using documents stored in a public UCSF database in an ongoing patent lawsuit, arguing they are protected by attorney–client privilege. The defendants say the files have long been public and may contain evidence relevant to Juul’s patent conduct.
Dec.29 by 2FIRSTS.ai
 Number of Vapers in Britain Surpasses Smokers for the First Time, Government Tightens Nicotine Regulations
Number of Vapers in Britain Surpasses Smokers for the First Time, Government Tightens Nicotine Regulations
For the first time, more people in Britain now vape than smoke. According to the Office for National Statistics (ONS), 10% of adults (5.4 million) regularly use e-cigarettes compared with 9.1% (4.9 million) who smoke cigarettes. The government credits vaping for the decline in smoking but plans tougher rules through the Tobacco and Vapes Bill, including a generational smoking ban and restrictions on nicotine pouch flavours, packaging, and sales.
Nov.05 by 2FIRSTS.ai
Alan Zhao: What Altria’s on! PLUS Authorization Really Signals About FDA PMTA Enforcement
Alan Zhao: What Altria’s on! PLUS Authorization Really Signals About FDA PMTA Enforcement
In this in-depth commentary for 2Firsts, Alan Zhao examines what Altria’s on! PLUS authorization really signals about FDA PMTA enforcement. Beyond the headline approval, FDA’s language, process design and product choices offer rare insight into how nicotine pouch regulation is taking shape—and what it means for industry compliance, in one of the earliest expert reads of the decision.
Regulations
Dec.20 by 2Firsts Perspectives